Zerotuss Oral Suspension contains Levocloperastine at a concentration of 20 mg per 5 ml and is indicated for the symptomatic relief of non-productive cough associated with various respiratory conditions. Levocloperastine is a non-opioid antitussive agent that acts centrally by suppressing the cough reflex without causing sedation or respiratory depression. This medication is particularly effective in reducing cough frequency and intensity, thereby improving patient comfort and quality of life. Zerotuss Oral Suspension is suitable for both adults and children, with dosage adjusted according to age and severity of symptoms. The formulation allows for easy administration and rapid onset of action. It is contraindicated in patients with hypersensitivity to Levocloperastine or any excipients present in the suspension. Caution is advised in individuals with a history of respiratory disorders or those taking other central nervous system depressants. Common adverse effects may include mild gastrointestinal disturbances or allergic reactions, though these are infrequent. Patients are advised to follow the prescribed dosage regimen and consult healthcare professionals if symptoms persist beyond one week or worsen. Zerotuss Oral Suspension offers a safe and effective option for managing dry cough, contributing to enhanced respiratory comfort and patient well-being.